Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TADPOL: DFMO in Type 1 Diabetes
NCT05594563Phase 2Active, not recruiting
- Start
- Mar 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eflornithine in type 1 diabetes mellitus (T1D). Started Mar 2023; status: active, not recruiting.
02
Drugs
eflornithine
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05594563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594563.